Skip to main content
Article
Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine.
Proceedings of the National Academy of Sciences (2010)
  • Miguel A. Villalona Calero, M.D.
Abstract
A phase II clinical trial with single-agent decitabine was conducted in older patients (>or=60 years) with previously untreated acute myeloid leukemia (AML) who were not candidates for or who refused intensive chemotherapy. Subjects received low-dose decitabine at 20 mg/m(2) i.v. over 1 h on days 1 to 10. Fifty-three subjects enrolled with a median age of 74 years (range, 60-85). Nineteen (36%) had antecedent hematologic disorder or therapy-related AML;
Publication Date
April 20, 2010
Citation Information
Miguel A. Villalona Calero. "Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine." Proceedings of the National Academy of Sciences Vol. 107 Iss. 16 (2010) p. 7473 - 7478
Available at: http://works.bepress.com/miguel-villalonacalero/62/